Aldehyde dehydrogenase family 18 member A1 (ALDH18A1) can posttranscriptionally regulate MYCN expression through the miR-29b/SP1 autoregulatory loop, and MYCN can transactivate ALDH18A1. The ALDH18A1 inhibitor YG1702 causes tumor regression and prolongs survival in a patient-derived xenograft (PDX) model of NB (Guo et al., 2020). Here, MYCN is linked to neoplasm.